Photothermal therapies to improve immune checkpoint blockade for cancer. (15th December 2020)

• Record Type: Journal Article
• Authors: Balakrishnan, Preethi B.; Sweeney, Elizabeth E.; Ramanujam, Anvitha S.; Fernandes, Rohan
• Is Part Of: International journal of hyperthermia. Volume 37:Number 3(2020)
• Page Start: 34
• Page End: 49
• Publication Date: 2020-12-15
• Subjects: Photothermal therapy -- nanoparticle -- immune checkpoint blockade -- immunotherapy -- cancer -- thermal ablation; Thermotherapy -- Periodicals; 615.832
• DOI: 10.1080/02656736.2020.1797190
• Languages: English
• ISSNs: 0265-6736

Abstract

Abstract: Immune checkpoint blockade (ICB) comprising monoclonal antibodies (mAbs) against immune 'checkpoints', such as CTLA-4 and the PD1/PDL1 axis have dramatically improved clinical outcomes for patients with cancer. However, ICB by itself has failed to provide benefit in a wide range of solid tumors, where recurrence still occurs with high incidence. These poor response rates may be due to the therapeutic shortcomings of ICB; namely, a lack of cancer-specific cytotoxicity and ability to debulk tumors. To overcome these limitations, effective ICB therapy may require the combination with other complementary therapeutic platforms. Here, we propose that photothermal therapy (PTT) is an ideal therapeutic modality for combination with ICB because it can generate both tumor-specific cytotoxicity and immunogenicity. PTT elicits these specific effects because it is a localized thermal ablation technique that utilizes light-responsive nanoparticles activated by a wavelength-matched laser. While ICB immunotherapy alone improves cancer immunogenicity but does not generate robust antitumor cytotoxicity, nanoparticle-based PTT elicits targeted and controlled cytotoxicity but sub-optimal long-term immunogenicity. Thus, the two platforms offer complementary and potentially synergistic antitumor effects, which will be detailed in this review. We highlight three classes of nanoparticles used as agents of PTT (i.e., metallic inorganic nanoparticles, carbon-based nanoparticles and organic dyes), and illustrate the potential for nanoparticle-based PTT to potentiate the effects of ICB in preclinical models. Through this discussion, we aim to present PTT combined with ICB as a potent synergistic combination treatment for diverse cancer types currently refractory to ICB as well as PTT monotherapies.